Indication: Endometrial Cancer
Title: SIENDO: Maintenance with selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer
Drug: selinexor

SIENDO is a Phase 3 study evaluating once weekly selinexor as a maintenance therapy versus placebo in patients with endometrial cancer after first- or second-line chemotherapy.


Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.

Rights

Drug: selinexor

PreclinicalPhase IPhase IIPhase III
Preclinical
Phase I
Phase II
Phase III